Amit Munshi - 21 Feb 2026 Form 4 Insider Report for Inhibikase Therapeutics, Inc. (IKT)

Reporting relationship: Director
Issuer ticker: IKT
Reported as of: 21 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Feb 2026, 20:48:55 UTC
Prior SEC filing: 08 Dec 2025
Next SEC filing: 09 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Mark Iwicki, attorney-in-fact

Key filing fact

Amit Munshi filed Form 4 for Inhibikase Therapeutics, Inc. (IKT) on 24 Feb 2026.

Key facts

This page summarizes Amit Munshi's Form 4 filing for Inhibikase Therapeutics, Inc. (IKT).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 24 Feb 2026, 20:48.

Change

Previous filing in this sequence was filed on 08 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001612551 Primary reporting owner

Munshi Amit

Relationship: Director
Address: 1000 N. WEST STREET, SUITE 1200, WILMINGTON
Signature: /s/ Mark Iwicki, attorney-in-fact
Signature date: 24 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IKT transaction

Common Stock

Disposed to Issuer

Transaction value: $0
Shares: -19,089
Change %: -33%
Price: $0.000000
Shares after: 38,176
Date: 21 Feb 2026
Ownership: Direct
Footnotes: F1

IKT holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 365,000
Date: 21 Feb 2026
Ownership: By Amit Munshi Revocable Trust

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

As previously reported on a Form 4 filed on August 28, 2025, the Reporting Person received shares of Issuer common stock as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. on February 21, 2025 (the "Closing Date"), with 19,089 shares subject to forfeiture if a certain milestone is not achieved by the first anniversary of the Closing Date. On February 21, 2026, it was determined that such milestone was not achieved, resulting in the forfeiture of all 19,089 shares. The Reporting Person received no consideration from the Issuer in connection with such forfeiture.